Topiramate weight loss in migraine patients

Alberici, Antonella; Borroni, Barbara; Manelli, Filippo; Griffini, Simona; Zavarise, Paola; Padovani, Alessandro; Volta, Giorgio Dalla

doi:10.1016/j.jns.2008.11.014

Cited by 18 publications

(16 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This last effect was observed in children with epilepsy 79 . Additional possible mechanisms may involve an induction of mitochondrial metabolism (seen in different animal models) 80 .…”

Section: Lorcaserinmentioning

confidence: 99%

New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

Catoira

Viale

Girolamo

et al. 2014

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…This last effect was observed in children with epilepsy 79 . Additional possible mechanisms may involve an induction of mitochondrial metabolism (seen in different animal models) 80 .…”

Section: Lorcaserinmentioning

confidence: 99%

New centrally acting agents for appetite control: from biological mechanisms to clinical efficacy

Catoira

Viale

Girolamo

et al. 2014

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…It is a weak carbonic anhydrase inhibitor, modulates the effects at GABA A receptors and AMPA receptors, and state dependently blocks Na + and Ca 2+ voltage-dependent channels ( Table 2) [3]. Although not specifi cally approved to treat obesity or food intake disorders, it has shown effi cacy in the treatment of these diseases as well [22]. Obese subjects lost between 5% and 6.3% of their body weight, depending on topiramate dosage.…”

Section: Topiramatementioning

confidence: 99%

“…Obese subjects lost between 5% and 6.3% of their body weight, depending on topiramate dosage. In one study, 37% of individuals using topiramate for migraines experienced a mean of 5.1 kg weight loss, whereas 63% reported no weight loss [22]. A separate retrospective analysis of 41 patients showed that 58.4% experienced weight loss (mean of 7.2 kg); however, those who did not lose weight actually gained an average of 5.0 kg (ie, it appeared to be a biphasic effect) [23].…”

Section: Topiramatementioning

confidence: 99%

“…A separate retrospective analysis of 41 patients showed that 58.4% experienced weight loss (mean of 7.2 kg); however, those who did not lose weight actually gained an average of 5.0 kg (ie, it appeared to be a biphasic effect) [23]. Weight loss in topiramate-treated epileptic patients has been attributed to a reduction in appetite and appears to plateau after about 6 months of therapy [22,24].…”

Section: Topiramatementioning

confidence: 99%

“…There also exists the rare possible side effect of severe defi cits in visual acuity, which has prompted early dis continuation [22].…”

Section: Topiramatementioning

confidence: 99%

See 2 more Smart Citations

What are the risks and the benefits of current and emerging weight-loss medications?

Robinson¹,

Niswender

2009

Curr Diab Rep

View full text Add to dashboard Cite

Obesity is epidemic; new medications and therapeutic options are urgently needed to reduce the associated health care burden. The initial clinical strategy for weight loss is lifestyle modification involving a combination of diet, exercise, and behavior change. However, it is difficult for many to achieve and maintain weight loss solely through this approach. Only two drugs, orlistat and sibutramine, have been approved by the US Food and Drug Administration (FDA) to treat obesity long term, and both medications have undesirable side effects, leaving an enormous unmet need for efficacious and safe therapy for obesity. Other medications with weight-loss effects have been approved by the FDA for short-term treatment of obesity or for disorders other than obesity, but these also have potential adverse effects. This article discusses the perceived benefits and risks of these approved medications along with emerging drugs that have shown weight-loss effects.

show abstract